POSITRON CORP Annual Report - How They Did This Year

I’ve put together this guide to help you understand Positron Corp’s latest annual report. My goal is to cut through the corporate jargon so you can decide if this company belongs in your portfolio.

1. What does this company do?

Positron Corp is a New York-based medical technology company that builds high-tech PET and PET-CT scanners. These machines use special tracers to create detailed images of the body’s metabolism, serving as the "gold standard" for doctors to diagnose heart disease, stage cancer, and identify neurological disorders like Alzheimer’s.

Positron operates as a niche player in a market dominated by massive conglomerates. Their primary goal is to replace older "SPECT" machines—which offer lower image quality and higher radiation—with their superior, more modern PET-CT technology.

2. The Big Strategy: The "Upgrade" Cycle

Positron is targeting the 10,000 older SPECT systems currently in U.S. clinics. They are executing this strategy through three main pillars:

• Lower Costs: By maintaining a lean operation, Positron prices their scanners 20% to 30% lower than giants like GE, Philips, and Siemens.
• Turnkey Support: They provide comprehensive service, including staff training, assistance with complex medical billing codes to ensure clinics get paid, and 24/7 technical support.
• Flexible Payments: They offer leases and "pay-per-scan" plans. This removes the barrier of the $1.5 million to $2.5 million upfront cost, making it easier for smaller hospitals to adopt their hardware.

3. Recent Wins and Developments

• Manufacturing Efficiency: A partnership with Neusoft Medical Systems allows Positron to outsource production. This keeps overhead costs low and provides the ability to scale production without the capital burden of building their own factories.
• Product Expansion: The launch of the Affinity™ PET-CT system, featuring advanced sensors for cancer and brain imaging, significantly expands the clinical utility of their technology.
• Operational Reliability: Their machines maintain a 98.5% uptime rate, which is a critical selling point for hospitals that lose significant revenue whenever a scanner is offline.

4. Financial Health & Risks

Investors should weigh these factors carefully:

• Revenue Mix: Currently, 60% of revenue comes from servicing legacy machines, while 40% comes from new hardware sales. Growth in the hardware segment is the primary indicator of successful market penetration.
• Market Listing: The stock trades on the OTC Pink Sheets. Because it does not trade on a major exchange, liquidity is lower and price volatility can be significant.
• Regulatory Dependency: The business model relies on Medicare and Medicaid fee schedules. Changes to these government payment rates directly impact the ability of hospitals to invest in new equipment.
• Capital Structure: The company carries significant debt and preferred stock. Potential conversion of these instruments into common shares could lead to dilution for current shareholders.

Bottom Line: Positron is a high-risk, high-reward play. They have a clear strategy to undercut industry giants, but success depends on their ability to capture market share in a highly regulated environment while managing a complex financial structure. Before investing, consider whether you are comfortable with the risks associated with OTC-listed, small-cap medical technology companies.